Navigation Links
Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
Date:10/4/2007

HAYWARD, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and CEO, will present at the BIO Investor Forum in San Francisco at the Palace Hotel on Thursday, October 11, 2007 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed through http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=KOSN&item_id=16576 63.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentation will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc. Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... MacArthur Sotheby’s International Realty, ... pleased to announce the first Delos Wellness Signature™ residence in Hawaii is on ... working together with listing agent Kelly Allen, R(S) of Carvill Sotheby’s International Realty ...
(Date:8/21/2017)... ... 21, 2017 , ... The team at Cell Signaling ... which attendees will learn about the assembly and topological architecture of mammalian SWI/SNF ... of the development and validation of new high-quality recombinant monoclonal antibodies, participants will ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... stock market news outlet had provided a research update on Aytu Bioscience and ... TRT product. , According to Soulstring, prescription rates for Natesto® have more than ...
(Date:8/16/2017)... Yorba Linda, Ca (PRWEB) , ... August 16, ... ... resist treatment by changing into a different cell type. Many treatments for specific ... tissue. A prominent example of targeted treatment is androgen deprivation therapy for advanced ...
Breaking Biology Technology:
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
(Date:3/23/2017)... report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), Product ... by MarketsandMarkets, the market is expected to be worth USD 18.98 billion by ... Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
Breaking Biology News(10 mins):